Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Highlights of This Issue

DOI:  Published September 2012
  • Article
  • Info & Metrics
  • PDF
Loading

Notch Inhibition in Pancreatic Cancer

Mizuma et al. Page 1999

Pancreatic cancer remains a lethal malignancy. Mizuma and colleagues used a panel of pancreatic cancer cell lines and patient-derived xenografts to show that targeting Notch signaling using a γ-secretase inhibitor, MRK-003, could downregulate Notch target genes and curb tumor-initiating pancreatic cancer stem cells, resulting in the inhibition of tumor growth and potentiation of gemcitabine sensitivity. Further, they identified a gene signature, responsive to Notch inhibition, which may aid in the selection of patient subsets more likely to benefit from this therapy. These findings convincingly establish the therapeutic relevance of the Notch signaling in pancreatic cancer and have major translational implications.

Sphingosine 1-Phosphate Lyase and Prostate Cancer

Brizuela et al. Page 1841

Sphingosine 1-phosphate (S1P) is a growth-promoting, proangiogenic and anti-apoptotic sphingolipid metabolite. This study reports the decrease activity and expression in prostate tumor samples of S1P lyase, the enzyme that degrades S1P. S1P lyase expression and activity were inversely correlated with those of sphingosine kinase-1, the enzyme producing S1P, and associated with tumor grade. S1P lyase and sphingosine kinase-1 expressions were independently predictive of aggressive cancer, supporting the role of S1P in prostate cancer. By decreasing S1P content, a dual strategy aimed at stimulating S1P lyase and inhibiting sphingosine kinase-1 made prostate cancer cells remarkably sensitive to chemotherapy or radiotherapy.

ABT-888 and Platinum Drug Combinations

Clark et al. Page 1948

Targeted therapy is an emerging option for BRCA-associated breast cancer patients. This study helps to illuminate one possible synergistic combination of conventional and novel agents. Using Brca/BRCA isogenic models (in vitro and in vivo), the cytotoxic effects of ABT-888 (PARP inhibitor), cisplatin, or carboplatin single agent treatments were compared to those in combinations and Clark and colleagues found that ABT-888/carboplatin combination was associated with enhanced cytotoxicity in BRCA-deficient models and that BRCA-deficient cells depend on a greater endogenous PARP activity (than BRCA-proficient cells) for survival. A phase II clinical trial is currently comparing ABT-888/carboplatin combination versus ABT-888 alone to treat BRCA-associated breast cancer patients.

TPI-287 Reduces Brain Metastatic Colonization

Fitzgerald et al. Page 1959

Brain metastases of breast cancer appear to be increasing in incidence and are significant contributors to patient morbidity and mortality. While the taxanes constitute a backbone chemotherapy for breast cancer, they are relatively brain impermeable. Here, Fitzgerald and colleagues identify a brain permeable member of the taxane family, TPI-287. TPI-287 prevented the formation of brain metastases by 55% in a mouse model system, but was unable to shrink established lesions.

  • ©2012 American Association for Cancer Research.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 11 (9)
September 2012
Volume 11, Issue 9
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Highlights of This Issue
Mol Cancer Ther September 1 2012 (11) (9) 1839;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlights of This Issue
Mol Cancer Ther September 1 2012 (11) (9) 1839;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Notch Inhibition in Pancreatic Cancer
    • Sphingosine 1-Phosphate Lyase and Prostate Cancer
    • ABT-888 and Platinum Drug Combinations
    • TPI-287 Reduces Brain Metastatic Colonization
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement